No Data
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 26.1%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 66,
Forward Pharma A/S (NASDAQ:FWP) & Avalo Therapeutics (NASDAQ:AVTX) Head to Head Survey
Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two busi
Avalo Therapeutics (NASDAQ:AVTX) Versus Forward Pharma A/S (NASDAQ:FWP) Head-To-Head Contrast
Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two business
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers IMARA Inc. (NASDAQ:IMRA) jumped 74.8% to settle at $2.01 on Wednesday after the company announced it entered into an asset purchase agreement with Cardurion Pharmaceuticals to sell tovinontrin
Avalo Therapeutics Begins IND-Enabling Studies of AVTX-008, Aims IND Submission in 2024
08:58 AM EDT, 09/06/2022 (MT Newswires) -- Avalo Therapeutics (AVTX) said Tuesday that AVTX-008, its human B and T lymphocyte attenuator agonist fusion protein, has begun studies that enable an invest
Avalo Therapeutics Announces AVTX-008 Has Entered IND-enabling Studies
Avalo Therapeutics announced that its human B and T Lymphocyte Attenuator agonist fusion protein, AVTX-008, has now entered IND-enabling studies, with a target IND submission date of 2024. The company
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
Strategy focused on LIGHT-signaling network targetsWAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced today that its human B and T L
Avalo to Present at the H.C. Wainwright Global Investment Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will presen
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 10.9%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 87,300 sha
Avalo Therapeutics Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Avalo Therapeutics (NASDAQ:AVTX) posted sales of $1.03 million. Earnings were up 41.1%, but Avalo Therapeutics still reported an overall loss of $12.99 milli
Loading...
